

# SOPHiA DDM™ Real-World Data Solutions

Transform your precision medicine journey with real-world insights



As biomarker-driven therapies target increasingly defined patient populations, access to timely, high-quality real-world insights has become critical to advance and de-risk drug development programs.

The **SOPHiA DDM™ Real-World Data (RWD) Solutions** enable BioPharma companies to:



**ACCELERATE  
TIMELINES**



**REFINE CDX  
STRATEGIES**



**OPTIMIZE  
MARKET ACCESS**

*Solidify your development and commercialization strategies with data-driven decisions*

## SOPHiA DDM™ Insights

Make confident, data-backed decisions throughout clinical development by revealing patterns and unmet needs.

Retrospective RWD insights from routine NGS testing to characterize patient populations, biomarker prevalence, and molecular epidemiology across geographies.

[Explore SOPHiA DDM™ Insights Mock Report](#)

Prospective RWD insights that translate into actionable market intelligence to support diagnostic adoption, medical education, and market access planning.

[Explore SOPHiA DDM™ Awareness Mock Report](#)

## SOPHiA DDM™ Awareness

Identify care gaps, prioritize regions and markets, and shape initiatives that improve testing practices and patient access.

Want to know more about our BioPharma offerings?

[GET IN TOUCH >](#)



### POPULATION CHARACTERIZATION

Understand the size, distribution, and molecular profile of your targeted populations.



### SITE PRIORITIZATION

Identify and rank sites with active profiling of biomarker-relevant patient populations.



### CARE GAPS

Reveal testing patterns to inform education, diagnostics, and access initiatives.



### MARKET ACCESS

Anticipate diagnostic and regional barriers by understanding real-world testing practices and readiness.

#### CASE STUDY #1

## SOPHiA DDM™ Insights Enables the Epidemiologic Landscape Study of *KIT* Mutations

Although the majority of Systemic Mastocytosis (SM) cases are driven by the *KIT* D816V mutation, little is known about the molecular profile characterization of the *KIT* gene to accurately diagnose SM.


**“ SOPHiA DDM™ Insights allows the accurate detection of *KIT* D816 point mutations and their co-occurrence with relevant oncogenes.**

References: Lamontagne, N. European Congress of Pathology [Poster Presentation]. 2023


*KIT* testing footprint in selected countries



*KIT* D816 point mutations distribution in the *KIT*-positive population



*KIT* D816V co-occurrence with other oncogenes




#### CASE STUDY #2

## SOPHiA DDM™ Awareness Reveals Liquid Biopsy Testing Adoption

Liquid biopsy is a promising, non-invasive diagnostic tool for cancer, yet its implementation in routine practice is still far from ideal.

**“ SOPHiA DDM™ Awareness helps assess and stay up to date with liquid biopsy adoption behaviours, supporting the identification of gaps in diagnostics and informing data-driven go-to-market and launch strategies.**

Total patients tested with Liquid Biopsy assay overtime



Distribution of liquid biopsy test per cancer type and associated oncogenes incidence

